Some potential biomarkers for endometrial cancer have been identified, including the most common somatic mutations in already well-known tumor-suppressor genes and oncogenes, such as the PTEN, TP53, POLE and KRAS mutations. This evidence concerns the gene PTEN and endometrial cancer.